Evidence map›Paper›PMID 34008317›Full record

Trial reportPharmaceutical statistics2021

The use of local and nonlocal priors in Bayesian test-based monitoring for single-arm phase II clinical trials.

Yanhong Zhou, Ruitao Lin, J Jack Lee

Abstract readClinical Trial, Phase II
In one paragraph

Trial report in Pharmaceutical statistics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yanhong ZhouDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center Houston, Houstan, Texas, USA.ORCID 0000-0003-2744-2100
Ruitao LinDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center Houston, Houstan, Texas, USA.ORCID 0000-0003-2244-131X
J Jack LeeDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center Houston, Houstan, Texas, USA.ORCID 0000-0001-5469-9214

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
TOLERANCE INDUCTION BY MEGADOSE STEM CELL TRANSPLANTS IN CML--GVHD AND GVLP01CA049639 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SHPALL, ELIZABETH J · 1990 to 2014
$41.8M
The University of Texas MD Anderson Cancer Center SPORE in MelanomaP50CA221703 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DAVIES, MICHAEL · 2019 to 2023
$10.3M
Bayesian Methods for Complex Precision Biotherapy Trials in OncologyR01CA261978 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LIN, RUITAO, THALL, PETER F · 2021 to 2024
$1.4M
NCI NIH HHS P01 CA049639NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA221703NCI NIH HHS R01 CA261978
6 · The paper itself

Abstract

Bayesian sequential monitoring is widely used in adaptive phase II studies where the objective is to examine whether an experimental drug is efficacious. Common approaches for Bayesian sequential monitoring are based on posterior or predictive probabilities and Bayesian hypothesis testing procedures using Bayes factors. In the first part of the paper, we briefly show the connections between test-based (TB) and posterior probability-based (PB) sequential monitoring approaches. Next, we extensively investigate the choice of local and nonlocal priors for the TB monitoring procedure. We describe the pros and cons of different priors in terms of operating characteristics. We also develop a user-friendly Shiny application to implement the TB design.

Indexed as

Research DesignBayes TheoremHumansProbabilityBayes factorlocal priornonlocal priorphase IIsequential monitoring

Identifiers

PMID34008317
PMCPMC9308506

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.